EUVIMEDEUVIMED entdecken
Open Access

CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy

Brian Thompson iD, Ann Strange iD, Carol M Amato iD, Jonathan Hester-McCullough iD, Amod A Sarnaik iD, Jeffrey S Weber, David M Woods iD

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2300250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Brian Thompson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Melanoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-infiltrating lymphocyte (TIL) adoptive cell therapy is effective in treating malignant melanoma, but its success relies on the adequate ex vivo expansion of TIL. To assess correlates of TIL expansion, CD4+ and CD8+ TIL were analyzed by RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing of acetylated histone 3. Patients were grouped into “TIL high” and “TIL low” based on division at the median number of TIL infused. Greater numbers of TIL infused correlated with longer overall survival, and increased frequencies of CD4+ cells infused were negatively correlated with the number of TIL infused. RNA-seq analysis of CD4+ TIL showed increases in Th2/Th17/regulatory T cell–related transcripts and pathways in the TIL-low group. Analysis of a public single-cell RNA-seq dataset validated findings that increased frequencies of CD4+ cells were negatively correlated with the number of TIL infused. TIL-low patients had significantly increased frequencies of CD4+ cells expressing ETS2 and OSM and trended toward increased expression of TNFRSF18.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingMelanomaHumansImmunotherapy, AdoptiveInterleukin-2Phenotype

Substanzen

Interleukin-2

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO.
  • Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.
  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY.

ORCID-Profile: Brian Thompson, Ann Strange, Carol M Amato, Jonathan Hester-McCullough, Amod A Sarnaik, David M Woods

Förderung

  • NCI NIH HHS
  • HHS | NIH | National Cancer Institute

Zitieren

APA

Thompson, B., Strange, A., Amato, C. M., Hester-McCullough, J., Sarnaik, A. A., Weber, J. S., & Woods, D. M. (2023). CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300250

Vancouver

Thompson B, Strange A, Amato CM, Hester-McCullough J, Sarnaik AA, Weber JS, et al. CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2300250

BibTeX
@article{Thompson2023,
  author = {Thompson, Brian and Strange, Ann and Amato, Carol M and Hester-McCullough, Jonathan and Sarnaik, Amod A and Weber, Jeffrey S and Woods, David M},
  title = {CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2300250}
}
Kostenlos starten →